Intraoperative dexmedetomidine reduces postoperative sleep disturbance in older adults undergoing major abdominal surgery
In a randomized, double-blind, placebo-controlled trial of 203 older adults (median age 71 years) undergoing major abdominal surgery, intraoperative dexmedetomidine infusion significantly reduced the relative risk of first-night postoperative sleep disturbance by 70-80% compared to normal saline. The incidence of first-night PSD was 65.7% in the saline group, 20.6% in the low-dose group (RR 0.31, 95% CI 0.19-0.50, NNT 2.2), and 11.8% in the high-dose group (RR 0.18, 95% CI 0.09-0.34, NNT 1.8).
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Intraoperative dexmedetomidine reduces postoperative sleep disturbance in older adults undergoing major abdominal surgery The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Intraoperative dexmedetomidine reduces postoperative sleep disturbance in older adults undergoing major abdominal surgery
This conclusion is most relevant to: Older adults (aged 65 or older) undergoing major abdominal surgery.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Intraoperative dexmedetomidine reduces postoperative sleep disturbance in older adults undergoing major abdominal surgery: a single-center, randomized, double-blind, placebo-controlled trial. (Communications medicine, 2026) —
How It Works
The proposed biological pathway:
- ▸Dexmedetomidine is a selective α2-adrenergic agonist
- ▸It promotes natural sleep by acting on the locus coeruleus
- ▸It provides sedative, analgesic, and anti-inflammatory effects
- ▸Result: Reduced postoperative sleep disturbance and improved recovery quality
Who Might Benefit
Evidence fit by population:
- ▸Older adults (aged 65 or older) undergoing major abdominal surgery
Recommended Dose
0.3 μg/kg/h or 0.6 μg/kg/h
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Single-center trial, which may limit generalizability
- ▸Exploratory actigraphy analysis had a small sample size (n=20 per group)
- ▸Findings require confirmation in multicenter trials
Frequently Asked Questions
What is postoperative sleep disturbance (PSD)?▼
PSD refers to poor sleep quality after surgery, measured in this study by an Athens Insomnia Scale score of 6 or higher on the first postoperative night.
How was dexmedetomidine administered in this study?▼
Dexmedetomidine was given as an intraoperative infusion at either 0.3 μg/kg/h (low-dose) or 0.6 μg/kg/h (high-dose) during major abdominal surgery.
Did dexmedetomidine cause any serious side effects?▼
No significant between-group differences were found in hypotension, bradycardia, delirium, or 30-day mortality, suggesting the treatment was well-tolerated.
Is this finding applicable to all older adults having surgery?▼
The study focused on older adults undergoing major abdominal surgery at a single center, so results may not generalize to other types of surgery or populations without further multicenter trials.
References
- 1.Peng HP, Hu JH, Fan LP, Yang X, Liu HY, Shan XS, Liu H, Sudhan N, Ji FH, Peng K. “Intraoperative dexmedetomidine reduces postoperative sleep disturbance in older adults undergoing major abdominal surgery: a single-center, randomized, double-blind, placebo-controlled trial..” Communications medicine, 2026. PMID: 42399418 DOI: 10.1038/s43856-026-01769-2